Skip to main content

Talk Bio

Search This Blog

Lilly's triple agonist heads to regulators after two more Phase 3 obesity wins

on July 23, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Eli Lilly's triple agonist, retatrutide, met primary endpoints in two additional Phase 3 obesity trials (TRIUMPH-2 and TRIUMPH-3), delivering up to ~20–22.6% weight loss at 80 weeks.

The drug is a once-weekly GIP, GLP-1, glucagon triple hormone receptor agonist, with one of the highest weight loss profiles seen in clinical trials to date.

Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027, with global regulatory submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea expected around the same timeframe.

Sources:

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C | Eli Lilly and Company

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

Lilly's 'triple G' agonist triumphs in Phase III trial, but AEs ...

New weight-loss shot appears to outperform other obesity drugs on market

Lilly Targets Early 2027 Filing for Next Obesity Drug

Eli Lilly Moves Closer To Another Weight-Loss Drug: Retatrutide Clears Two More Phase 3 Trials Ahead Of FDA Filing

Lilly's triple agonist delivers up to 71.2 lbs of weight loss

28.3% Weight Loss Confirmed (Complete ... - Retatrutide 2026

Phase III Clinical Trials

ADA: Lilly offers deeper glimpse into triple-G obesity ...

Retatrutide Clinical Trials & Results - glp3.wiki

Lilly's triple-acting obesity drug hits goal in Phase 3 trial

Lilly retatrutide Phase 3 Lilly triple agonist FDA Obesity trials TRIUMPH-2 TRIUMPH-3

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC